Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

Delgermaa, 2011, Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008, Bull World Health Organ, 89, 716, 10.2471/BLT.11.086678

Beebe-Dimmer, 2016, Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival, Clin Epidemiol, 8, 743, 10.2147/CLEP.S105396

Baas, 2015, Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 26, v31, 10.1093/annonc/mdv199

Zalcman, 2016, Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial, Lancet, 387, 1405, 10.1016/S0140-6736(15)01238-6

Postow, 2015, Immune checkpoint blockade in cancer therapy, J Clin Oncol, 33, 1974, 10.1200/JCO.2014.59.4358

Bograd, 2011, Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma, Cancer Immunol Immunother, 60, 1509, 10.1007/s00262-011-1103-6

Hegmans, 2006, Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses, Eur Respir J, 27, 1086, 10.1183/09031936.06.00135305

Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239

Wolchok, 2013, Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials, Ann Oncol, 24, 2174, 10.1093/annonc/mdt161

Ribas, 2005, Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206, J Clin Oncol, 23, 8968, 10.1200/JCO.2005.01.109

Khan, 2011, Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells, Clin Immunol, 138, 85, 10.1016/j.clim.2010.09.011

Calabrò, 2013, Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial, Lancet Oncol, 14, 1104, 10.1016/S1470-2045(13)70381-4

Calabrò, 2015, Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study, Lancet Respir Med, 3, 301, 10.1016/S2213-2600(15)00092-2

Calabrò, 2015, CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?, Cancer Immunol Immunother, 64, 105, 10.1007/s00262-014-1609-9

Calabrò, 2015, Immune checkpoint blockade in malignant mesothelioma, Semin Oncol, 42, 418, 10.1053/j.seminoncol.2015.02.001

Byrne, 2004, Modified RECIST criteria for assessment of response in malignant pleural mesothelioma, Ann Oncol, 15, 257, 10.1093/annonc/mdh059

Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026

Curran, 1998, Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience, J Clin Oncol, 16, 145, 10.1200/JCO.1998.16.1.145

Wolchok, 2009, Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, Clin Cancer Res, 15, 7412, 10.1158/1078-0432.CCR-09-1624

Burman, 2009, A recycling framework for the construction of Bonferroni-based multiple tests, Stat Med, 28, 739, 10.1002/sim.3513

Klein, 2007, Analyzing survival curves at a fixed point in time, Stat Med, 26, 4505, 10.1002/sim.2864

Mirabelli, 2009, Survival of peritoneal malignant mesothelioma in Italy: a population-based study, Int J Cancer, 124, 194, 10.1002/ijc.23866

Krug, 2011, VANTAGE 014: Vorinostat (V) in patients with advanced malignant pleural mesothelioma (MPM) who have failed prior pemetrexed and either cisplatin or carboplatin therapy: a phase III randomized, double-blind, placebo-controlled trial, Eur J Cancer, 47, 2, 10.1016/S0959-8049(11)70098-3

Eroglu, 2015, Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab, Eur J Cancer, 51, 2689, 10.1016/j.ejca.2015.08.012

McDermott, 2014, Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma, Cancer Treat Rev, 40, 1056, 10.1016/j.ctrv.2014.06.012

Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466

Camacho, 2015, CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations, Cancer Med, 4, 661, 10.1002/cam4.371

Weber, 2012, Management of immune-related adverse events and kinetics of response with ipilimumab, J Clin Oncol, 30, 2691, 10.1200/JCO.2012.41.6750

Bertrand, 2015, Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis, BMC Med, 13, 211, 10.1186/s12916-015-0455-8

Spain, 2016, Management of toxicities of immune checkpoint inhibitors, Cancer Treat Rev, 44, 51, 10.1016/j.ctrv.2016.02.001

Rizvi, 2015, Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348

Parmiani, 2015, Integrating immune checkpoint blockade with anti-neo/mutated antigens reactivity to increase the clinical outcome of immunotherapy, Vaccines, 3, 420, 10.3390/vaccines3020420

Bueno, 2016, Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations, Nat Genet, 48, 407, 10.1038/ng.3520

Jassem, 2008, Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma, J Clin Oncol, 26, 1698, 10.1200/JCO.2006.09.9887

Quispel-Janssen J, Zimmerman M, Buikhuisen W. Nivolumab in malignant pleural mesothelioma (NIVOMES): an interim analysis. Proceedings of the 13th International Conference of the International Mesothelioma Interest Group; Birmingham, UK; May 1–4, 2016. abstr 284.

Hassan, 2016, Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: safety, clinical activity, and PD-L1 expression, J Clin Oncol, 34

Kindler, 2017, Phase II trial of pembrolizumab in patients with malignant mesothelioma (MM): interim analysis, J Thorac Oncol, 12

Curran, 2010, PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors, Proc Natl Acad Sci USA, 107, 4275, 10.1073/pnas.0915174107

Antonia, 2016, Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study, Lancet Oncol, 17, 299, 10.1016/S1470-2045(15)00544-6

Hellmann, 2017, Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study, Lancet Oncol, 18, 31, 10.1016/S1470-2045(16)30624-6

Thapa, 2016, Immunotherapy for malignant mesothelioma: reality check, Expert Rev Anticancer Ther, 16, 1167, 10.1080/14737140.2016.1241149